Overview

A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration

Status:
Completed
Trial end date:
2016-04-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, bioactivity and pharmacokinetics of three concentrations of DE-120 after a single intravitreal injection in subjects with late stage exudative age-related macular degeneration.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Santen Inc.
Treatments:
Pharmaceutical Solutions